| | |
| Clinical data | |
|---|---|
| Other names | HR-459 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H19N3 |
| Molar mass | 289.382 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Perafensine (INN; development code HR-459) is a drug which was investigated as an antidepressant but was never marketed. [1] It has been reported to antagonize the effects of reserpine and to inhibit the reuptake of norepinephrine (norepinephrine reuptake inhibitor); whether it also affects the reuptake of serotonin or dopamine is unclear. [2]